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INTRODUCTION
The anatomic location of a primary malignancy significantly
affects a patient’s prognosis. The overall cure rate for patients
with cancer of the oropharynx is usually low, and the use of sur-
gery involves complex surgical procedures, including reconstruc-
tion. During the initial work up, patients with cancer of the oro-
pharynx must be stratified to determine their prognosis and man-
agement. Currently, the TNM classification is the most common-
ly used system for stratifying the prognosis. However, the TNM
system fails to define the true three-dimensional tumor volume
within a given stage of disease. 
Therefore, a superficial tumor with a good prognosis may be
categorized in the same T-stage group as a deeply infiltrated tu-
mor with a poor prognosis. Tumor volume is known to be a sig-
nificant prognostic indicator for cancers of the head and neck re-
gion (1). However, there is controversy about using the tumor
volume for guiding patient management.
The purpose of this study was to determine the clinical effica-
cy of the primary tumor volume, as measured by a 3D reconstruc-
tion program (Rapidia
�, Infinite, Seoul, Korea), at different pri-
mary sites in the oropharynx, as compared with that of the pri-
mary tumor volume in the oral cavity.
MATERIALS AND METHODS
Patients
We conducted a retrospective analysis of the patients with can-
cer of the oral cavity or oropharynx after they finished their pri-
mary treatment, and all the patients were treated at the Korea
University Hospital from 1995 through 2007. The patients who
had not finished their primary treatment, those who had a dou-
ble primary cancer or who had non-epithelial cell types of can-
cer were excluded from this study. We also excluded the patients
whose imaging scans could not be reconstructed by the 3D recon-
struction program used for the study. Most of the excluded images
were from old model computed tomography (CT)/magnetic res-
onance imaging (MRI) scanners that were not compatible with
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Original Articlethe 3D reconstruction program. Eighty-five patients were final-
ly included in this study.
The study group was composed of 43 patients with oral cavi-
ty cancer (24 men and 19 women, mean age: 55.9 yr, range: 25
to 76 yr, mean follow up: 25.6 months, range: 1 to 79 months)
and 42 patients with oropharynx cancer (29 men and 13 women,
mean age: 59.6 yr, range: 28 to 85 yr, mean follow up: 33.3 mon-
ths, range: 4 to 105 months). The primary sites of the oral cavi-
ty cancers were the tongue (n=27), the floor of the mouth (n=6),
the buccal mucosa (n=3), the gingiva (n=2), the hard palate (n=1),
the retromolar trigone (n=3) and the lip (n=1). The American
Joint Committee on Cancer (AJCC) stage was Stage I in 8 pati-
ents, Stage II in 12, Stage III in 8 and Stage IV in 15 patients. The
sites of the primary lesions in the patients with cancer of the oro-
pharynx were the tonsil (n=26), the base of the tongue (n=13)
and the soft palate (n=3). The AJCC stage was Stage I in 2 pati-
ents, Stage II in 6, Stage III in 8 and Stage IV in 26 patients.
Our institutional therapy protocol differed based on the TNM
stage, the surgical accessibility of the primary tumor, the response
to radiation therapy, the postoperative pathology report and the
patient’s choice (Table 1). The patients with early stage disease
underwent primary surgery or radiation alone. Elective neck
treatment was performed if the risk of an occult neck metastasis
was significant (Ipsilateral neck treatment if the tumor was lat-
eralized and bilateral neck treatment if the tumor extended be-
yond the midline). 
The patients with positive neck nodes received a therapeutic
neck dissection. Postoperative radiotherapy was performed for
the patients with close or involved resection margins, perineur-
al or vascular invasion, multiple neck metastasis, an advanced
stage or extracapsular nodal spread.
Combined modality treatments were provided for most of the
advanced stage patients. However, some of the patients with clini-
cal stage IV disease did not receive postoperative radiation ther-
apy. One patient refused radiation therapy because of the con-
cern about the potential complications. One patient was noted
to have lung metastasis right after surgery. One patient with a
history of a full course of radiation treatment at another head
and neck site declined additional radiation therapy. 
Tumor volume measurement
The tumor area was manually outlined from the best images of
the pretreatment axial magnetic resonance (MR) series among
the T1, T2 and gadolinium-enhanced T1-weighted images (Fig.
1). We used the CT images if there were no MRI scans available
at the time of diagnosis (this was the case for 3 oral cavity can-
cer patients and 9 oropharynx cancer patients). A single board-
certified otolaryngologist, who was kept “blind” to all the other
clinical information, systematically outlined every primary lesion
that was recognizable on each scan slice with the assistance of a
head and neck radiologist who had 20 yr of experience. The soft-
ware was used to automatically calculate the areas of the lesions
and, from the thickness of the slice, the volume of tumor per slice
and, finally, the sum of the volumes of all the slices. To reduce
the measurement error, the same image was separately reviewed
twice and the average value was regarded as the final tumor vol-
ume. The values of the primary tumor volumes were then sub-
divided into separate groups based on the ranked tumor volumes
(≤3,500 mm
3, >3,500 mm
3) (Fig. 2).
Statistical analysis
The prognostic indicators we studied were age, gender, the site
of the primary tumor, the primary tumor volume (≤3,500 mm
3
or >3,500 mm
3), the cT status and the cN status. All of the vari-
ables were first analyzed independently to estimate their effect
on the overall survival (OS) (the interval between the date of
diagnosis and the date of death from any cause or the most recent
follow-up), and the disease-free survival (DFS) (from the end of
treatment to the date of tumor recurrence or death from disease).
The survival rates were calculated by the Kaplan-Meier method,
and the differences between the survival curves were statistical-
ly analyzed with the log-rank test. The Cox model was used to
determine the independent effects of the studied variables on
survival. Associations between the primary tumor volume and
neck metastasis (ipsilateral/contralateral) were examined by Fi-
sher’s exact test. A P-value of 0.05 or less was considered to be
statistically significant. 
RESULTS
Association of the primary tumor volume with the prognosis Fig.
2 shows the distribution of the primary tumor volume and this
illustrates that there was substantial variation in the primary tu-
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PS PS+NS PS+RT
PS+NS+ PR or 
Total
RT CCRT
OC OPX OC OPX OC OPX OC OPX OC OPX OC OPX
Table 1. The treatment modality that was performed at various sta-
ges of the oral cavity/oropharynx cancer. The patients with early
stage disease underwent primary surgery or radiation alone. Elective
neck treatment was done if the risk of an occult neck metastasis was
significant (Ipsilateral neck treatment if the tumor was lateralized and
bilateral neck treatment if the tumor extended beyond the midline).
The patients with a clinically positive neck node received therapeu-
tic neck dissection. The patients with lymph node metastasis, resec-
tion margins with tumor invasion or an advanced tumor stage under-
went postoperative radiotherapy
PS: primary site surgery; NS: neck surgery; RT: postoperative radiotherapy;
PR: primary radiation therapy; CCRT: chemoradiation therapy; OC: oral cavi-
ty; OPX: oropharynx.
AJCC
stage
Stage I 3 0 3 1 2 1 0 0 0 0 8 2
Stage II 0 1 5 0 3 2 4 2 0 1 12 6
Stage III 0 0 4 0 0 1 4 5 0 2 8 8
Stage IV 0 0 3 1 0 1 11 21 1 3 15 2680 Clinical and Experimental Otorhinolaryngology  Vol. 2, No. 2: 78-84, June 2009
Fig. 1. An example of measuring the primary tumor volume with using the 3D reconstruction program. (A) The gadolinium-enhanced, T1-weight-
ed axial MR images of a tonsil cancer patient and (B) manual tracing of the area of the tumor. The tumor area is manually outlined (blue line) from
the sequential sections. This allows the software to automatically calculate the areas of the lesions and, from the thickness of the slice, the volume
of the tumor per slice and finally, the sum of the volumes of all the slices. (C) Pre-tracing the CT image of the same patient and (D) post-tracing
the CT image.
A B
C D
Fig. 2. Distribution of the primary tumor volumes in the oral cavity (A) and the oropharynx (B). There was substantial variation of the primary tumor
volume for the same stage lesions and a great deal of overlap among tumors at different stages, and especially those at the advanced stage.
Therefore, the two-dimensional T stages do not reflect the actual three-dimensional tumor volume. We subdivided the patients into two volume
groups based on the cutoff value of 3,500 mm
3.
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mor volumes for lesions with the same T stage and there was a
great deal of overlap for lesions with different T stages, and espe-
cially at the advanced stages. The results of the univariate and
multivariate analyses for the prognostic factors for the OS and
DFS are shown in Tables 2 and 3. When age, the primary site,
the cT stage, the cN stage and the primary tumor volume were
grouped as in Table 1, the prognostic indicators that were sig-
nificantly associated with OS or DFS were the cT stage and cN
stage (for oral cavity cancer); age, the site of the primary can-
cer, the cT stage, the cN stage and the primary tumor volume
(for oropharynx cancer) were significant on the univariate analy-
sis (Table 2). However, none of the factors were significant for
the patients with oral cavity cancer on the multivariate analysis.
However, the primary site, the cN stage and the primary tumor
volume were independent prognostic factors for patients with
oropharynx cancer on the multivariate analysis (Table 3). Fig. 3
demonstrates the difference in the survival plots between the
patients with oral cavity cancers and the patients with the orophar-
ynx cancers. The primary tumor volume, as a prognostic indica-
tor, was significant only for the patients with oropharynx can-
cer. The patients with a large oropharynx tumor volume had a
significantly poorer OS and DFS than those patients with a small
oropharynx tumor volume.
Association of the primary tumor volume with neck
metastasis
The oropharyngeal primary tumor volume was significantly grea-
ter for patients with contralateral metastatic nodes as compared
to the patients without metastasis (Fisher’s exact test, P=0.004).
However, there was no significant correlation with ipsilateral
neck metastases (Fisher’s exact test, P=0.443). In addition, there
was no significant correlation between the primary tumor vol-
ume and the ipsilateral or contralateral lymph node metastasis
in patients with oral cavity cancer (Fisher’s exact test, P=0.255,
P=0.161). 
DISCUSSION
Our results show that the primary tumor volume was an indepen-
dent prognostic indicator not only for survival, but also for local/
regional disease recurrence. However, this correlation was obser-
ved for the patients with cancer of the oropharynx and not for
the patients with oral cavity cancer. The findings of this study also
demonstrated a correlation between the primary tumor volume
*Statistically significant.
OC: oral cavity; OPX: oropharynx; OS: overall survival; DFS: disease-free survival; PTV: primary tumor volume.
% Survival
OS DFS
OC OPX OC OPX
Table 2. Univariate analysis of the prognostic factors for overall survival and disease-free survival
No. of patients
Variables
OC OPX
Prognostic indicators
Age ≤60 25 19 88 63.2 76 57.9
>60 18 23 83.3 87 77.8 78.3
P=0.544 P=0.05* P=0.944 P=0.12
Gender Male 24 29 79.2 72.4 70.8 65.5
Female 19 13 94.7 84.6 84.2 76.9
P=0.186 P=0.324 P=0.346 P=0.41
Site of cancer 
Oral cavity  Tongue  27 88.9 81.5
Other sites 16 81.3 68.8
P=0.55 P=0.327
Oropharynx Tonsil  26 92.3 80.8
Other sites 16 50 50
P=0.001* P=0.027*
Clinical T stage  T1-3  34 34 91.2 88.2 79.4 79.4
T4 9 8 66.7 25 66.7 25
P=0.035* P=0.00* P=0.321 P=0.002*
Clinical N stage  N 0-1  32 18 93.8 88.9 77.4 88.9
N 2-3 11 24 63.6 66.7 75 54.2
P=0.033* P=0.05* P=0.788 P=0.009*
PTV ≤3,500 mm
3 23 16 95.7 93.8 87 93.8
>3,500 mm
3 20 26 75 65.4 65 53.8
P=0.152 P=0.05* P=0.147 P=0.009*82 Clinical and Experimental Otorhinolaryngology  Vol. 2, No. 2: 78-84, June 2009
and contralateral neck metastases in the patients with cancer of
the oropharynx. Therefore, the primary tumor volume, as a pro-
gnostic indicator, is not applicable to all the head and neck regions.
The differences in the tumor biology, the lymphatic distribution,
the pattern of lymphangiogenesis and the mechanism of the lym-
phatic invasion may have contributed to the observed differences.
Kimura et al. (1) have reported similar results; they showed a sig-
nificant correlation between the tumor volume and lymph node
metastasis for the patients with oropharyngeal or hypopharyn-
geal cancer, but not for the patients with oral or maxillary sinus
cancer.
The primary tumor volume has often been studied as a prog-
nostic indicator to complement the limitations of the two-dimen-
sional AJCC staging system. Le Tourneau et al. (2) reported that
the tumor volume should be considered as an essential prognos-
tic indicator for patients with head and neck cancers. Mancuso
et al. (3) reported that tumors ≥6 cm
3 had a 52% local control
rate as compared to an 89% control rate for those tumors <6 cm
3
among 63 patients with supraglottic laryngeal cancer that was
treated with definitive radiation therapy. Lo et al. (4) reported
that the local control rate for >4 cm
3 T2 laryngeal tumors was
significantly lower than that for ≤4 cm
3 T2 laryngeal tumors.
Chao et al. (5) found that the tumor volume was the most impor-
tant predictive factor for the IMRT response in patients with ad-
vanced oropharyngeal carcinoma. Doweck et al. (6) observed
that the primary tumor volume was correlated with local disease
control and survival for patients with head and neck cancer. Jo-
hnson et al. (7) studied 51 cases of advanced squamous cell car-
cinoma of the head and neck. They found an adverse effect of
the tumor volume on the local/regional disease control. Johnson
et al. (8) evaluated 76 patients with advanced head and neck can-
cer. They concluded that the tumor volume had better prognos-
tic power than did the TNM stage. Chang et al. (9) reviewed 76
patients with T3/T4 nasopharyngeal cancer and they reported
that the tumor volume was the only independent prognostic vari-
able identified.
Fig. 3. Comparison of the survival plots between the patients with oropharynx and those with oral cavity cancers. (A) The Kaplan-Meier plot of the
disease-free survival as assessed by the primary tumor volume and according to univariate analysis, P=0.009 (oropharynx cancer), (B) the over-
all survival as assessed by the primary tumor volume and according to univariate analysis, P=0.05 (oropharynx cancer), (C) multivariate study
with Cox proportional hazard multivariate analysis, P=0.032 (oropharynx cancer) and (D) the Kaplan-Meier plot of the disease-free survival accord-
ing to the primary tumor volume. As compared to the patients with oropharynx cancer, there was no significant relationship between the prima-
ry tumor volume and disease recurrence for the patients with oral cavity cancers (univariate test, P=0.147, oral cavity cancer).
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C DHowever, measuring the tumor volume is a laborious process
that is performed by manual tracing the tumor outline. The orig-
inal technique for evaluating the tumor volume was complex and
time-consuming. Moreover, tumor volume measurement is rather
subjective and inter-reader or intrareader errors are possible (1,
10). However, Gordon et al. (11) showed that these errors were
not significant when performing MR imaging-based tumor vol-
ume measurement. In addition, the recent advances in radiolo-
gy imaging and the three-dimensional treatment-planning sys-
tems have enabled us to quantify the tumor volume more easi-
ly and accurately. We used a 3D reconstruction program to mea-
sure the tumor volume, and it was a fast, reproducible and reli-
able method.
Most of the primary tumor volume measurements were calcu-
lated with using the MR images. If a MR image was not available,
then we used a CT image. The MR images have been shown to
be more accurate for measuring tumor volume than using the CT
images, and especially for tumors of the oral cavity and orophar-
ynx, if the tissue contrast between the tumor and the surround-
ing tissue is insufficient on the CT images (12-15% of the cases)
or if artifacts cover the tumor on the CT images or if the tumor
is very small (stage T1 or T2) (12). However, some reports have
shown that the tumor volume of pharyngolarynx tumors, as cal-
culated with the CT and MR imaging, did not exhibit significant
differences (13).
The limitations of this study include that the tumor volume ana-
lysis was not stratified separately based on the different T stages,
the anatomic subsites and the various treatment modalities due
to the small number of patients. Other limitations were the rela-
tively short follow-up period and the study’s retrospective design.
Therefore, prospective analysis of a large cohort of patients is
warranted.
In summary, the results of this study demonstrate that the pri-
mary tumor volume measurement was a reliable method for stra-
tifying the outcomes of patients with oropharynx tumor. The ab-
solute measures of the tumor volume by the 3D reconstruction
program were significantly predictive of the OS and DFS for pa-
tients with oropharynx cancer, but not for the patients with oral
cavity cancer. The addition of the primary tumor volume mea-
surement to the current AJCC staging system can compensate
for some of the limitations of AJCC staging. However, its useful-
ness depends on the primary site of the tumor in the head and
neck region.
REFERENCES
1. Kimura Y, Sumi M, Ichikawa Y, Kawai Y, Nakamura T. Volumetric
MR imaging of oral, maxillary sinus, oropharyngeal, and hypopharyn-
geal cancers: correlation between tumor volume and lymph node metas-
tasis. AJNR Am J Neuroradiol. 2005 Oct; 26(9):2384-9.
2. Le Tourneau C, Velten M, Jung GM, Bronner G, Flesch H, Borel C.
Prognostic indicators for survival in head and neck squamous cell car-
cinomas: analysis of a series of 621 cases. Head Neck. 2005 Sep;27(9):
801-8.
3. Mancuso AA, Mukherji SK, Schmalfuss I, Mendenhall W, Parsons J,
Pameijer F, et al. Preradiotherapy computed tomography as a predic-
tor of local control in supraglottic carcinoma. J Clin Oncol. 1999 Feb;
17(2):631-7.
4. Lo SM, Venkatesan V, Matthews TW, Rogers J. Tumour volume: im-
plications in T2/T3 glottic/supraglottic squamous cell carcinoma. J Oto-
laryngol. 1998 Oct;27(5):247-51.
5. Chao KS, Ozyigit G, Blanco AI, Thorstad WL, Deasy JO, Haughey BH,
et al. Intensity-modulated radiation therapy for oropharyngeal carcino-
ma: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2004 May
1;59(1):43-50.
6. Doweck I, Denys D, Robbins KT. Tumor volume predicts outcome for
advanced head and neck cancer treated with targeted chemoradiother-
apy. Laryngoscope. 2002 Oct;112(10):1742-9.
7. Johnson CR, Thames HD, Huang DT, Schmidt-Ullrich RK. The tumor
volume and clonogen number relationship: tumor control predictions
based upon tumor volume estimates derived from computed tomogra-
Chung E-J et al.: Primary Tumor Volume Measurements 83
Prognostic 
Primary Exp (B) 95% CI P-value
indicators
Table 3. Multivariate analysis of the prognostic factors for overall sur-
vival and disease-free survival
OC: oral cavity; OPX: oropharynx; OS: overall survival; DFS: disease-free
survival.
OS
Age  ≤60 OC 0.413 0.071-2.398 0.324
>60 OPX 1.736 0.219-13.741 0.601
Gender Male OC 2.434 0.207-28.633 0.479
Female OPX 0.492 0.055-4.388 0.525
Site of cancer
Oral cavity Tongue OC 0.642 0.098-4.213 0.644
Other sites
Oropharynx Tonsil OPX 0.078 0.009-0.642 0.018*
Other sites
Clinical T  T1-3 OC 0.516 0.067-3.954 0.524
stage T4 OPX 0.867 0.149-5.041 0.873
Clinical N  N 0-1 OC 0.432 0.062-3.028 0.398
stage N 2-3 OPX 0.124 0.012-1.246 0.076
Primary tumor   ≤3,500 mm
3 OC 0.272 0.017-4.303 0.356
volume >3,500 mm
3 OPX 0.187 0.017-2.076 0.172
DFS
Age  ≤60 OC 0.767 0.197-2.984 0.702
>60 OPX 1.123 0.237-5.326 0.884
Gender Male OC 1.516 0.348-6.592 0.579
Female OPX 0.584 0.111-3.064 0.525
Site of cancer
Oral cavity Tongue OC 0.573 0.142-2.315 0.434
Other sites
Oropharynx Tonsil OPX 0.151 0.025-0.931 0.042*
Other sites
Clinical T  T1-3 OC 1.378 0.25-7.604 0.713
stage T4 OPX 1.163 0.235-5.763 0.853
Clinical N  N 0-1  OC 0.696 0.168-2.88 0.617
stage N 2-3 OPX 0.084 0.013-0.541 0.009*
Primary tumor ≤3,500 mm
3 OC 0.386 0.075-1.981 0.254
volume >3,500 mm
3 OPX 0.086 0.009-0.813 0.032*84 Clinical and Experimental Otorhinolaryngology  Vol. 2, No. 2: 78-84, June 2009
phy. Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):281-7.
8. Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese J 3rd, Wa-
zer DE. The influence of quantitative tumor volume measurements on
local control in advanced head and neck cancer using concomitant boost
accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys.
1995 Jun 15;32(3):635-41.
9. Chang CC, Chen MK, Liu MT, Wu HK. The effect of primary tumor
volumes in advanced T-staged nasopharyngeal tumors. Head Neck. 2002
Oct;24(10):940-6.
10. Weiss E, Hess CF. The impact of gross tumor volume (GTV) and clin-
ical target volume (CTV) definition on the total accuracy in radiother-
apy theoretical aspects and practical experiences. Strahlenther Onkol.
2003 Jan;179(1):21-30.
11. Gordon AR, Loevner LA, Shukla-Dave A, Redfern RO, Sonners AI,
Kilger AM, et al. Intraobserver variability in the MR determination of
tumor volume in squamous cell carcinoma of the pharynx. AJNR Am
J Neuroradiol. 2004 Jun-Jul;25(6):1092-8.
12. Lenz M, Greess H, Baum U, Dobritz M, Kersting-Sommerhoff B. Oro-
pharynx, oral cavity, floor of the mouth: CT and MRI. Eur J Radiol.
2000 Mar;33(3):203-15.
13. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler
H, et al. Tumor volume in pharyngolaryngeal squamous cell carcino-
ma: comparison at CT, MR imaging, and FDG PET and validation with
surgical specimen. Radiology. 2004 Oct;233(1):93-100. 